Skip to main content
Premium Trial:

Request an Annual Quote

BostonGene Liquid Biopsy, Immunoprofiling, and Spatial Proteomics Solutions

BostonGene has launched its CLIA-certified and CAP-accredited liquid biopsy, immunoprofiling, and spatial proteomics solutions that the company said provide a "holistic" view of a patient's disease by integrating multiple AI-based molecular and immune profiling techniques. The liquid biopsy solution offers high-sensitivity pan-cancer interrogation of 216 genes, including 200 genes with complete exonic coverage, the company said. The company's proprietary error reduction algorithms and filtration of hematopoietic (CHIP) mutations provide accurate testing results, it added. The immunoprofiling solution uses a single tube of blood to identify surrogate biomarkers for clinical trial patient selection, monitor disease progression and treatment response, and guide immunotherapy treatment, BostonGene said. The spatial proteomics offering comprises a multiplex immunofluorescence assay to provide a comprehensive overview of tumor cells, active and suppressive immune cell infiltration, stromal and vascular components, and advanced analytics of tissue architecture based on cell-to-cell interactions, the company said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.